Stay updated on Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page
- Check5 days agoChange DetectedUpdated the page to Revision v3.0.2, replacing v3.0.1. The 'Back to Top' element was removed.SummaryDifference0.2%
- Check12 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%
- Check19 days agoChange DetectedThe web page has undergone significant updates, including the addition of new facility and location information, as well as detailed medical content related to neoplastic processes and the drug pembrolizumab. The previous version's references to certain locations and specific antineoplastic agents have been removed.SummaryDifference3%
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check41 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check48 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.